Boule Diagnostics AB (publ) (STO:BOUL)
Sweden · Delayed Price · Currency is SEK 6.34
+0.08 (1.28%)
Aug 6, 2025, 5:29 PM CET
Theseus Pharmaceuticals Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 515.86 | 558.46 | 571.33 | 548.09 | 463.34 | 400.46 | Upgrade | |
Revenue Growth (YoY) | -9.90% | -2.25% | 4.24% | 18.29% | 15.70% | -19.73% | Upgrade |
Cost of Revenue | 284.53 | 303.33 | 321.62 | 320.18 | 264.71 | 223.27 | Upgrade |
Gross Profit | 231.33 | 255.13 | 249.71 | 227.91 | 198.64 | 177.19 | Upgrade |
Selling, General & Admin | 123.89 | 146.89 | 153.35 | 143.6 | 120.15 | 110.94 | Upgrade |
Research & Development | 53.4 | 37.8 | 53.09 | 51.57 | 43.33 | 43.05 | Upgrade |
Other Operating Expenses | - | - | - | -0.74 | -0.7 | -0.79 | Upgrade |
Operating Expenses | 177.29 | 184.69 | 206.44 | 194.43 | 162.78 | 153.19 | Upgrade |
Operating Income | 54.04 | 70.44 | 43.27 | 33.48 | 35.86 | 24 | Upgrade |
Interest Expense | -14.79 | -12.59 | -11.3 | -9.85 | -5.49 | -4.21 | Upgrade |
Interest & Investment Income | 1.29 | 1.39 | 1.14 | 1.78 | 1.35 | 0.31 | Upgrade |
Earnings From Equity Investments | - | - | - | - | - | -40.28 | Upgrade |
Currency Exchange Gain (Loss) | -2.68 | -6.48 | -3.01 | -4.5 | -2.95 | -0.47 | Upgrade |
Other Non Operating Income (Expenses) | -0.2 | 0 | 0 | -0 | -0 | 0 | Upgrade |
EBT Excluding Unusual Items | 37.67 | 52.77 | 30.1 | 20.9 | 28.77 | -20.66 | Upgrade |
Merger & Restructuring Charges | -22.8 | -22.8 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | -0.05 | - | 0.08 | Upgrade |
Asset Writedown | -400.22 | -390.72 | - | - | - | -40.05 | Upgrade |
Other Unusual Items | - | - | - | - | - | 11.6 | Upgrade |
Pretax Income | -385.35 | -360.75 | 30.1 | 20.85 | 28.77 | -49.02 | Upgrade |
Income Tax Expense | -65.67 | -64.17 | 5.12 | 8.12 | 5.5 | -1.06 | Upgrade |
Net Income | -319.68 | -296.58 | 24.98 | 12.73 | 23.27 | -47.97 | Upgrade |
Net Income to Common | -319.68 | -296.58 | 24.98 | 12.73 | 23.27 | -47.97 | Upgrade |
Net Income Growth | - | - | 96.24% | -45.31% | - | - | Upgrade |
Shares Outstanding (Basic) | 39 | 39 | 39 | 28 | 27 | 19 | Upgrade |
Shares Outstanding (Diluted) | 39 | 39 | 39 | 28 | 27 | 19 | Upgrade |
Shares Change (YoY) | -0.22% | - | 36.37% | 4.65% | 40.14% | - | Upgrade |
EPS (Basic) | -8.21 | -7.64 | 0.64 | 0.46 | 0.87 | -2.47 | Upgrade |
EPS (Diluted) | -8.22 | -7.64 | 0.64 | 0.45 | 0.86 | -2.47 | Upgrade |
EPS Growth | - | - | 42.22% | -47.67% | - | - | Upgrade |
Free Cash Flow | 3.58 | 37.68 | 44.51 | -17.79 | 40.14 | 70.65 | Upgrade |
Free Cash Flow Per Share | 0.09 | 0.97 | 1.15 | -0.63 | 1.48 | 3.64 | Upgrade |
Dividend Per Share | - | - | - | - | 0.550 | 0.550 | Upgrade |
Gross Margin | 44.84% | 45.68% | 43.71% | 41.58% | 42.87% | 44.25% | Upgrade |
Operating Margin | 10.48% | 12.61% | 7.57% | 6.11% | 7.74% | 5.99% | Upgrade |
Profit Margin | -61.97% | -53.11% | 4.37% | 2.32% | 5.02% | -11.98% | Upgrade |
Free Cash Flow Margin | 0.69% | 6.75% | 7.79% | -3.25% | 8.66% | 17.64% | Upgrade |
EBITDA | 68.93 | 87.53 | 60.41 | 54.14 | 51.17 | 41.48 | Upgrade |
EBITDA Margin | 13.36% | 15.67% | 10.57% | 9.88% | 11.04% | 10.36% | Upgrade |
D&A For EBITDA | 14.89 | 17.09 | 17.14 | 20.66 | 15.31 | 17.48 | Upgrade |
EBIT | 54.04 | 70.44 | 43.27 | 33.48 | 35.86 | 24 | Upgrade |
EBIT Margin | 10.48% | 12.61% | 7.57% | 6.11% | 7.74% | 5.99% | Upgrade |
Effective Tax Rate | - | - | 17.02% | 38.95% | 19.11% | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.